• LAST PRICE
    4.8000
  • TODAY'S CHANGE (%)
    Trending Down-0.2000 (-4.0000%)
  • Bid / Lots
    ---/ ---
  • Ask / Lots
    ---/ ---
  • Open / Previous Close
    5.0000 / 5.0000
  • Day Range
    Low 4.8000
    High 5.0000
  • 52 Week Range
    Low 3.5000
    High 14.0000
  • Volume
    1,203
    above average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Monday's close: 5
TimeVolumeQSAM
09:32 ET3505
09:35 ET1504.848
10:09 ET3004.925
10:11 ET4004.8
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesQSAM
Qsam Biosciences Inc
9.6M
-0.8x
---
United StatesCDIO
Cardio Diagnostics Holdings Inc
9.6M
0.0x
---
United StatesBPTS
Biophytis SA
8.8M
-0.1x
---
United StatesVRPX
Virpax Pharmaceuticals Inc
9.5M
-0.5x
---
United StatesVRAX
Virax Biolabs Group Ltd
9.5M
-5.0x
---
United StatesKTRA
Kintara Therapeutics Inc
9.8M
-0.3x
---
As of 2023-01-31

Company Information

QSAM Biosciences, Inc. is developing nuclear medicines for the treatment of cancer and related diseases. The Company’s technology, CycloSam (Samarium-153 DOTMP), is a clinical-stage bone targeting radiopharmaceutical developed by IsoTherapeutics Group LLC. Iso Therapeutics Group LLC is also developed a commercial radiopharmaceutical on the market, Quadramet (Samarium-153 EDTMP), which is indicated for pain palliation. CycloSam consists of a combination of the radioactive isotope Samarium-153 and the chelant DOTMP (1,4,7,10-tetraazacyclododecanetetramethylene-phosphonic acid). Its combination delivers a radioactive dose to sites of bone mineral turnover, such as bone cancers and tumors. CycloSam has a physical half-life of approximately 46 hours and emits both medium-energy beta particles, which produce the therapeutic effect and gamma photons that make it possible to locate the anatomical distribution. Its subsidiary is QSAM Therapeutics Inc.

Contact Information

Headquarters
9442 CAPITAL OF TEXAS HWY N PLAZA 1, SUITE 500AUSTIN, TX, United States 78759
Phone
512-343-4558
Fax
302-655-5049

Executives

Executive Chairman of the Board
C. Richard Piazza
Chief Executive Officer, Director
Douglas Baum
Chief Financial Officer
Adam King
General Counsel
Christopher Nelson
Independent Director
Charles Link

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$9.6M
Revenue (TTM)
$0.00
Shares Outstanding
1.9M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
2.34
EPS
$-5.89
Book Value
$0.17
P/E Ratio
-0.8x
Price/Sales (TTM)
---
Price/Cash Flow (TTM)
---
Operating Margin
---
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.